Ondine Biomedical Inc.
OBI.L · LSE
12/31/2024 | 6/30/2024 | 12/31/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Revenue | £668 | £865 | £767 | £432 |
| % Growth | -22.8% | 12.8% | 77.6% | – |
| Cost of Goods Sold | £371 | £606 | £593 | £475 |
| Gross Profit | £297 | £259 | £174 | -£43 |
| % Margin | 44.5% | 29.9% | 22.7% | -10% |
| R&D Expenses | £3,320 | £3,325 | £2,924 | £2,205 |
| G&A Expenses | £0 | £0 | £0 | £0 |
| SG&A Expenses | £3,492 | £4,821 | £3,954 | £5,854 |
| Sales & Mktg Exp. | £0 | £0 | £0 | £0 |
| Other Operating Expenses | £0 | £0 | £0 | £0 |
| Operating Expenses | £6,812 | £8,146 | £6,878 | £8,059 |
| Operating Income | -£6,515 | -£7,887 | -£6,704 | -£8,102 |
| % Margin | -976% | -911.6% | -874.3% | -1,876.1% |
| Other Income/Exp. Net | £156 | £68 | £260 | £131 |
| Pre-Tax Income | -£6,359 | -£7,818 | -£6,443 | -£7,971 |
| Tax Expense | £0 | -£3,301 | £0 | £0 |
| Net Income | -£6,359 | -£7,818 | -£6,443 | -£7,971 |
| % Margin | -952.6% | -903.6% | -840.2% | -1,845.8% |
| EPS | -0.021 | -0.019 | -0.032 | -0.041 |
| % Growth | -12.3% | 41.9% | 21.3% | – |
| EPS Diluted | -0.021 | -0.019 | -0.032 | -0.041 |
| Weighted Avg Shares Out | 303,075 | 241,469 | 200,098 | 194,716 |
| Weighted Avg Shares Out Dil | 303,075 | 241,469 | 200,098 | 194,716 |
| Supplemental Information | – | – | – | – |
| Interest Income | £18 | £0 | £38 | £206 |
| Interest Expense | £14 | £22 | £18 | £20 |
| Depreciation & Amortization | £158 | £286 | £279 | £308 |
| EBITDA | -£6,187 | -£4,218 | -£6,424 | -£7,794 |
| % Margin | -926.9% | -487.5% | -837.7% | -1,804.8% |